Global Strategic Report
April 2016; 175 Pages
This global strategic report evaluates strategies across the entire stem cell product spectrum, with emphasis on opportunities for stem cell research product development. It explores unique market opportunities by stem cell type, including mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and more.
The possibilities arising from stem cells have resulted in great commercial interest, with potential applications ranging from their use in the reversal of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, toxicology assessment, and more.
Several broad categories of stem cells exist, including:
- Embryonic stem cells, derived from blastocysts
- Perinatal stem cells, obtained during the period immediately before and after birth
- Adult stem cells, found in adult tissues
- Induced pluripotent stem cells, produced by genetically reprogramming adults cells
- Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body
Traditionally, scientists have worked with both embryonic and adult stem cells as research tools. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral and spiritual controversy surrounding their use. Although some adult stem cells do have differentiation capacity, it is often limited, which results in fewer options for use.
Thus, when induced pluripotent stem cells (iPSCs) were produced from mouse cells in 2006 by Shinya Yamanaka of Kyoto University in Japan, they represented a promising combination of adult and embryonic stem cell characteristics. By 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSC cells. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.
At this time, the following account for the majority of stem cell research:
- Basic Research – Understanding stem cell mechanisms and behavior
- Regenerative Medicine– Use of stem cells for the reversal of injury or disease
- Drug Target Validation and Drug Delivery– Validation of the predicted target using living cells
- Toxicology Screening– Use of stem cells to evaluate effects of drugs on biological systems
To facilitate research resulting from interest in these potential far-ranging applications, a large and growing stem cells research products market has emerged.
Large companies selling stem cell research products include:
- Thermo Fisher Scientific
- BD Biosciences, a Division of Becton Dickinson
- Merck KGaA
- Miltenyi Biotec
- STEMCELL Technologies
- Lonza Group
- Clontech (a Takara Bio Company)
- GE Healthcare Life Sciences.
While several of these dominant market players have utilized acquisition strategies to grow and capture market share, Merck KGaA has had a particularly strong commitment to this approach, acquiring several other massive major players within the stem cell research products marketplace, including Milllipore on February 26, 2010, for $7.2 billion, and Sigma-Aldrich on September 22, 2014, for $17 billion. Dozens of mid-sized suppliers of stem cell research products also exist, as well as over 100 small specialty providers.
Currently, the following compose the majority of stem cell research product sales worldwide:
- Primary antibodies to stem cell antigens
- Bead-based stem cell separation systems
- Fluorescent-based labeling and detection
- Stem cell protein purification and analysis tools
- Tools for DNA and RNA-based characterization of stem cells
- Isolation/characterization services
- Stem cell culture media and reagents
- Stem cell specific growth factors and cytokines
- Tools for stem cell gene regulation
- Stem cell services and mechanisms for in vivoand in vitro stem cell tracking
- Expansion/differentiation services for stem cell media and RNAi
- Stem cell lines
Key report findings include:
- Market size determinations, with 5-year projections for the stem cell research products market (2016-2020)
- Year-over-year analysis of stem cell grant rates, patent rates, clinical trial rates, and scientific publication rates
- Stem cell funding sources, trends, and amounts (domestic and international)
- Stem cell research applications, including priorities by segment
- Relative demand for stem cell products, by stem cell type
- Breakdown of stem cell product categories
- Competitive analysis of leading stem cell research product companies
- Online trends for stem cells, including Google Trends and Google Adwords
- Social analytics for stem cells, including activity on Twitter, LinkedIn, Facebook, and more
- Communications strategies for accessing the marketplace
- End-user survey of stem cell scientists
End-User Survey of 289 Stem Cell Scientists
A distinctive feature of this report is an end-user survey of 289 researchers worldwide that identify as having stem cells as their research focus. These survey findings reveal researcher needs, technical preferences, key factors influencing buying decisions, and more.
The findings can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.
Claim this report to acquire an understanding of stem cell market trends, efficiently target emerging opportunities, and accurately identify the current and future needs of your client base.
The content and statistics contained in this report were compiled using a broad range of sources. These input sources include:
- Stem Cell Grant Funding Database (RePORT Database, CIRM, MRC, Wellcome Trust – UK)
- Stem Cell Patent Database (United States Patent and Trade Office, World Intellectual Property Organization)
- Stem Cell Clinical Trial Database (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register )
- Stem Cell Scientific Publication Database (PubMed, Highwire Press, Google Scholar)
- Stem Cell Product Launch Announcements (Trade Journals, Google News)
- Stem Cell Industry Events (Google News, Google Alerts)
- Stem Cell Company News (SEC Filings, Investor Publications, Historic Performance)
- Social Analytics Platforms (Google Trends, Google Adwords, BuzzSumo, Hashtagify.me)
- International Surveys (Electronically Distributed End-User Survey)
- And More
Greater than 100% Money Back Guarantee
Remember, all BioInformant products come with a Greater Than 100% Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money, and you can keep the product.
12-Months of Free Consultation
Your product is also accompanied by 12-Months of Free Consultation on this market segment from our team of stem cell experts (value of $2,995). You will be given phone and email details for a BioInformant team member who you can contact anytime with questions that you have about this market segment. BioInformant is well-suited to serve your needs, because we now have a full decade of historical information on stem cell market (2006 to present).
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
To claim this report, fill out this Purchase Form or select the License Option you prefer from the pull-down menu below to immediately download your product.
|Thumbnail||License||Price||Quantity||Add to Cart Button|
|Single User + Hard Copy||$3,895|